Neural stem cells (NSCs) led to the development of a novel strategy for delivering therapeutic genes to brain tumors. Human NSCs expressing rabbit carboxyl esterase (F3.CE), which activates CPT-11, significantly inhibit the growth of A549 human non-small cell lung adenocarcinoma cells in the presence of CPT-11 in vitro and in vivo. F3.CE cells migrated selectively into the brain metastases located in the opposite hemisphere. The treatment also significantly decreased tumor volume in immune-deficient mice bearing lung cancer when F3.CE cells were transplanted into the contralateral hemisphere. The survival of tumor-bearing animals was significantly prolonged by the treatment with F3.CE and CPT-11. This strategy could be considered as an effective treatment regimen for lung cancer brain metastases.
INTRODUCTION
Brain metastasis is the most common intracranial neoplasm and arises in 10-40% of all cancer patients. Because metastases in the brain may rapidly compromise the central nervous system (CNS) function, it is a significant cause of cancer-related morbidity and mortality worldwide. 1 Primary lung cancer has the highest incidence for brain metastasis, and approximately 40% of all patients with lung cancer develop brain metastasis during the course of the disease. 2 A solitary brain metastasis can be managed by surgery or radiation. However, many patients harbor multiple metastases, making such management impractical. 3 The use of systemic chemotherapeutics or the use of whole-brain irradiation would be possible solutions. However, radiation therapy can cause negative side effects such as impaired cognitive function and radiation necrosis, and chemotherapy is usually insufficient, as delivery to the brain is problematic because of blood-brain barrier and induces drug resistance. 4 This calls for development of a new treatment approach designed to target brain metastases.
Recently, the discovery of the inherent tumor-tropic properties of neural stem cells (NSCs) provides a novel approach to potentially overcome the primary challenge in developing chemotherapeutic regimens. 5 The use of therapeutic NSCs is highly attractive as delivery vehicles that disseminate therapeutic gene products specifically to multi-site and invasive tumor cells. 6 In previous studies, we have reported that the human NSCs carrying therapeutic suicide genes, such as cytosine deaminase (CD) that convert prodrug 5-fluorocytosine into tumorcidal 5-fluorouracil [7] [8] [9] [10] [11] [12] [13] [14] and carboxyl esterase (CE) that hydrolyzes the prodrug CPT-11 (Irinotecan) to a topoisomerase 1 inhibitor (SN-38; 7-Ethyl-10-hydroxy-camptothecin), [15] [16] [17] were highly effective in treating brain tumors. Recently, we have used human NSCs expressing yeast cytosine deaminase gene (yCD) or cytosine deaminase-herpes simplex thymidine kinase fusion gene (CD-HSVtk) for treatment of experimental animals bearing brain metastases of lung cancer and observed a marked reduction in tumor size and prolonged animal survival. 14, 18 In this study, HB1.F3 (F3) human NSCs were transduced with CE gene and transplanted in mice bearing brain metastases from lung cancer, and administration of prodrug CPT-11 followed. We wish to establish the proof of concept that brain metastases can be effectively targeted using this approach.
MATERIALS AND METHODS

Cell culture
HB1.F3 (F3), a stably immortalized human NSC cell line, was derived from human fetal telencephalon at 15 weeks of gestation by introducing a retroviral vector encoding v-myc. [19] [20] [21] F3 and F3 cells encoding rabbit CE (F3.CE) gene were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS, Invitrogen, Grand Island, NY, USA), 2 mmol L-glutamine, 100 units ml À 1 penicillin and 100 mg ml À 1 streptomycin (DMEM-10% FBS). A549 human non-small cell lung adenocarcinoma cell line was purchased from the Korean Cell Line Bank (Seoul, Korea) and maintained in DMEM-10% FBS.
Genetic engineering of F3.CE human NSC line
The clonal F3.CE human NSC line was derived from the parental F3 NSC line. An expression plasmid-encoding rabbit CE was constructed using the retroviral pIRESneo (Clontech, Palo Alto, CA, USA) as previously described. 20 The methods of transduction and establishment of stable cell lines were previously reported. 22 Successful transduction of the F3.CE cells was confirmed by reverse transcription PCR (Figure 1a ) using the primer pair:
To confirm the activity of CE in F3.CE cells, the cytotoxic effect of CPT-11 on F3 or F3.CE cells was analyzed using a cell viability assay. F3 or F3.CE cells (1 Â 10 4 per well) were plated in 96-well plates. Twenty-four hours after seeding, 0.5-10 mM of CPT-11 (Hanmi Pharmaceutical, Seoul, Korea) was applied for 48 h, and the status of the cells was analyzed using a microscope, and viability was determined with a colorimetric assay (Cell Counting Kit-8; Dojindo Molecular, Gaithersburg, MD, USA).
In vitro bystander effect experiments A549 human non-small cell lung adenocarcinoma cells were plated in 96-well plates with F3 or F3.CE cells (A549 cells: F3 or F3.CE cells ¼ 75:25, 50:50, 25:75, or 0:100). A549 and F3 or F3.CE cells were maintained in DMEM-10% FBS. After 24 h of cell growth, 10 mM CPT-11 was added to the mixed cell cultures, and, 48 h later, cell viability was determined as described above.
Lung cancer brain metastasis animal models
Animal experiments in this study have been reviewed and approved by the Animal Care and Use Committee of Chung-Ang University (Certification CA11-0086). For direct tumor cell implantation into the brain, anesthetized SCID mice (7 weeks old) were secured in a rodent stereotaxic frame and a hollow guide screw introduced through a small drill hole made at 2 mm left and 1 mm anterior to the bregma, and 1 Â 10 6 A549 human lung cancer cells in 4 ml phosphate buffered saline (PBS) were injected through this guide screw into the brain at a depth of 2 mm (anterior/posterior (AP) þ 1.0 mm, medial/lateral (ML) þ 1.7 mm, dorsal/ventral (DV) À 3.2 mm).
In vivo therapeutic efficacy of F3.CE human NSCs
We evaluated four study groups (control, F3.CE, CPT-11 and F3.CE/CPT-11), containing eight mice per group. Thirteen and twenty days after A549 cell injection, animals were subjected to intracardiac arterial injection of 100 ml of PBS (control and CPT-11 groups) or 1 Â 10 6 F3.CE cells in 100 ml PBS (F3.CE and F3.CE/CPT-11 groups). Forty-eight hours after the F3.CE injection, the control and F3.CE group received intraperitoneal injections of normal saline (100 ml), whereas CPT-11 and F3.CE/CPT-11 group received CPT-11 (3.75 mg kg À 1 in 100 ml normal saline) everyday for 5 days. Two days after the last injection, brains were removed and cut into 4-6 mm thick coronal slices. For tumor volume measurement (largest width 2 Â largest length Â 0.5), the brain slices were fixed in 10% formalin in phosphate-buffered saline (PBS), embedded in paraffin, sectioned into 4 mm sections using a microtome and stained with H&E.
For survival analysis, seven mice per each group were treated as described and observed for evidence of a symptomatic intracranial mass such as incoordination, lethargy or weight loss425% of maximal body weight. At 2 days after last injection, two mice from each group underwent head magnetic resonance image scanning to evaluate tumor growth in vivo. Magnetic resonance image scans were obtained using a clinical 4.7-T Bruker Biospin imager (Bruker Medical Systems, Karlsruhe, Germany) using the following parameters: TR, 300.0 ms; TE, 12.0 ms; partition thickness, 0.94 mm; field of view (FOV), 12.0 cm x 4.0 cm; and matrix size, 256 Â 256. If the weight loss 425% of maximal body weight was identified during observation, afterward, it was regarded as mortality and then the animal was euthanized.
Statistics
Statistical comparisons were performed using the Student's t-test. Survival analysis was performed using the Kaplan-Meier and log rank tests. P-values o0.05 were considered statistically significant.
RESULTS
F3.CE human NSC cells expressing rabbit CE
Expression of CE gene in the F3.CE cells was analyzed by reverse transcription-PCR ( Figure 1a ). As expected, CE transcript was detected in F3.CE cells but not in parental F3 cells. To confirm the function of CE, F3.CE cells were exposed to CPT-11 at concentrations of 0.5-10 mM for 48 h. The survival of F3.CE cells was reduced considerably by 48 h exposure to prodrug CPT-11 at concentrations of o1 mM (Figure 1b) . When F3 control cells and F3.CE cells were exposed to 10 mM CPT-11 for 48 h, o20% of F3.CE cells survived, whereas 475% of control F3 cells survived, indicating that F3.CE cells processed prodrug CPT-11 efficiently into cytotoxic SN-38 and underwent suicidal cell death (Figure 1c) .
In vitro bystander effects on lung cancer cells Next, the in vitro bystander effects of F3.CE cells on A549 lung cancer cells were determined using the F3.CE-A549 co-culture system and conditioned medium derived from F3 or F3.CE cells. In the co-culture experiment, application of 10 mM CPT-11 to A549 human lung cancer cells had little effects on the survival until 48 h after the treatment (data not shown). Toxic effects of CPT-11 (10 mM) were not observed when A549 cells were co-cultured with Figure 2 ). Without CPT-11, co-culture with F3 or F3.CE had no effect on the survival of A549 cells (data not shown).
In vivo therapeutic efficacy of F3.CE human NSCs Timeline for the establishment of lung cancer brain metastasis animal model and subsequent treatment using F3.CE cells and CPT-11 is shown in Figure 3 .
Thirteen and twenty days after stereotaxic A549 cancer cell implantation into the brains of immune-deficient mice, animals were subjected to intracardiac injection of saline (control and CPT-11 group) or F3.CE cells (F3.CE and F3.CE/CPT-11 group). Fortyeight hours after the NSC injection, the control and F3.CE groups received intraperitoneal injections of normal saline, whereas the other two groups received intraperitoneal injections of CPT-11 (3.75 mg kg À 1 ) everyday for 5 days after each NSC injection. In magnetic resonance imaging scans performed at 2 days after last CPT-11 injection, tumor-bearing animals treated with F3.CE and CPT-11 showed a significant reduction in tumor volume (Figure 4 top) . Brain sections prepared from animals treated with F3.CE and CPT-11 showed a significant reduction in tumor size (Figure 4 bottom) . Multiple metastatic tumors were observed both in the magnetic resonance image and H&E-stained brain sections of control animals and animals transplanted with F3.CE cells without additional CPT-11 treatment (Figure 4) .
The in vivo therapeutic efficacy of F3.CE cells against lung cancer brain metastasis was determined by tumor volume measurement and survival analysis.
When tumor volumes were determined in brain tissue 2 days after the last CPT-11 injection, the brains of the mice of F3.CE/ CPT-11 group showed significantly reduced tumor volumes (median ± s.d. 
DISCUSSION
In the present study, we have shown that NSCs can specifically target primary and distant metastatic lung cancer. This stem cellbased lung cancer therapy should be readily translatable to clinical studies, as is currently being used in an investigational phase I clinical trial in adult patients with recurrent glioblastoma (clinical trial ID NCT01172964;http://clinicaltrials. gov/ct2/show/ NCT01172964).
The use of NSCs as drug delivery vehicles may offer a major therapeutic breakthrough for treatment of metastatic lung cancer, by localizing high concentrations of chemotherapeutic agent selectively to tumor sites, thus overcoming some major limitations of currently available treatment strategies. Recent studies have found that immortalized and genetically engineered NSCs have advantages that could be useful for gene therapy for the treatment of brain tumors. 6, 23 We have previously reported that F3 human NSCs engineered to express Escherichia coli cytosine deaminase (CD) respond to the administration of prodrug 5-fluorocytosine (5-FC) and reduced brain tumor growth both in vitro and in vivo. [7] [8] [9] [10] [11] [12] [13] [14] We have also reported that the transplanted F3 NSCs encoding CE gene (F3.CE) selectively migrate to brain tumor sites and show therapeutic effect on subdural medulloblastoma 15 and brain metastases of breast cancer. 16, 17 NSCs were engineered to secrete rabbit carboxylesterase (CE), an enzyme that activates the prodrug CPT-11 (irinotecan) to the active drug SN-38, a 1000-fold more potent topoisomerase I inhibitor that preferentially kills dividing cells, thereby concentrating chemotherapy specifically to tumor ) was injected intraperitoneally for 5 days. The mice were divided into four groups as follows: in group 1, the mice were treated with 100 ml PBS as a negative control; in group 2, the mice were treated with F3.CE cells in 100 ml PBS (intracardiac injection) in the absence of CPT-11; in group 3, the mice were treated only with CPT-11 (10 mM, 3.75 mg kg ). At 2 days following last CPT-11 injection, all mice were euthanized and brains were processed for histology.
sites. CPT-11 is approved for malignant glioma and is currently in phase II trials for malignant gliomas. 24, 25 CPT-11 is one of the chemotherapeutic drug, which can penetrate blood-brain barrier effectively, and plausible agent to treat brain malignant lesions, demonstrating promising results in a number of experimental brain tumors. [15] [16] [17] 23 Considering systemic toxicity of the CPT-11, including interference in the immune function and leukopenia, severe gastrointestinal disturbance, and hepatotoxicity, [25] [26] [27] however, the main obstacles to clinical application of CPT-11 in metastatic brain tumor is the dosage adjustment to balance the efficacy over the adverse toxicity. Presently, this problem has been tried to be solved by combining additional chemotherapeutic agents, such as bevacizumab, that can synergize the anti-tumor activity by interrupting tumor growth through different biological mechanism. 26 Local CE delivery strategy in this study might be another effective method to maximize cytotoxic efficacy to the disseminated brain lesions without causing hazardous systemic influence of the drug, and it may open the possibility of gaining or even enhancing the outcome of conventional combination regimen.
For targeting metastatic brain tumors using a NSC-based approach, we have previously reported studies using human NSCs encoding suicide genes cytosine deaminase or carboxyl esterase in animals bearing brain metastasis of breast cancer 10 and lung cancer 14, 18 and NSCs encoding CE in brain metastases of breast cancer models. 16, 17 The present study demonstrates that the brain transplantation of human NSCs, encoding the suicide enzyme CE, combined with systemic administration of CPT-11 could be considered as an effective treatment regimen for brain metastases of lung cancer. To the best of our knowledge, this is the first preclinical study of therapeutic efficacy of human metastatic brain tumor from lung cancer using CE gene delivery. We believe the model presented here could be applied to other metastasis and can guide the development of future metastasis therapeutics. 
